Watch ANIP. Know when insiders buy.
One email the day a filing lands. Free.
Work order
15
FLAG · insiders 29, shorts 0
Insiders, 90 days
−$609K
net selling · 0 buys, 2 sells
Congress, 90 days
0 / 0
no disclosures naming it
Big money
0 / 15
none of the tracked funds disclose it
Calls on record
0
nobody we score has called it yet
MKT CAP $1.8BP/E 15.5DIV YIELD —FCF YIELD 9.84%REV TTM $978.4M +30.9%NET INCOME $108.3MNET CASH $226.1M52W 70.49 – 98.81SEC XBRL · TTM TO Invalid Date
Financials
By quarter
| Period | Revenue | YoY | Gross margin | Operating income | Net income | YoY | EPS | Op. cash flow | Capex | Free cash flow | Filed |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Q2 2026 · Jun 30 | $266M | +25.9% | — | $40.5M | $24.7M | +189.1% | 1.05 | $56.7M | $3.1M | $53.6M | Aug 7 |
| Q1 2026 · Mar 31 | $237.5M | +20.5% | — | $38.9M | $29.5M | +88.1% | 1.28 | $58.4M | $6.1M | $52.3M | May 8 |
| Q4 2025 · Dec 31derived | $247.1M | +29.6% | — | $34.8M | $27.5M | — | 1.17 | $30.4M | $1.2M | $29.1M | Feb 27 |
| Q3 2025 · Sep 30 | $227.8M | +53.6% | — | $36.2M | $26.6M | — | 1.13 | $44.1M | $6.1M | $38M | Nov 7 |
| Q2 2025 · Jun 30 | $211.4M | +53.1% | — | $13.9M | $8.5M | — | 0.36 | $75.8M | $4M | $71.8M | Aug 7 |
| Q1 2025 · Mar 31 | $197.1M | +43.4% | — | $26.2M | $15.7M | −13.9% | 0.69 | $35M | $2.5M | $32.5M | May 8 |
| Q4 2024 · Dec 31derived | $190.6M | +44.8% | — | −$4.4M | −$10.3M | −989.7% | -0.55 | $15.9M | $2.4M | $13.5M | Feb 27 |
| Q3 2024 · Sep 30 | $148.3M | +12.5% | — | −$20.5M | −$24.2M | −343.1% | -1.27 | $12.5M | $4.8M | $7.7M | Nov 7 |
| Q2 2024 · Jun 30 | $138M | — | — | $5.2M | −$2.3M | — | -0.14 | $17.4M | $4.4M | $13M | Aug 8 |
| Q1 2024 · Mar 31 | $137.4M | — | — | $20.3M | $18.2M | — | 0.82 | $18.3M | $4.6M | $13.7M | May 9 |
| Q4 2023 · Dec 31derived | $131.7M | — | — | $6.7M | $1.2M | — | 0.02 | $44.7M | $2.3M | $42.5M | Feb 27 |
| Q3 2023 · Sep 30 | $131.8M | — | — | $17.9M | $9.9M | — | 0.45 | $32.2M | $1.7M | $30.4M | Nov 8 |
By fiscal year
| Year | Revenue | Gross margin | Operating income | Net income | Net margin | EPS | Op. cash flow | Capex | Free cash flow | Buybacks | Dividends paid |
|---|---|---|---|---|---|---|---|---|---|---|---|
| FY2025 · to Dec 31 | $883.4M | — | $111.1M | $78.3M | 8.9% | 3.32 | $185.2M | $13.8M | $171.4M | $12.2M | $1.2M |
| FY2024 · to Dec 31 | $614.4M | — | $584K | −$18.5M | -3.0% | -1.04 | $64M | $16.2M | $47.8M | $11M | $1.6M |
| FY2023 · to Dec 31 | $486.8M | — | $47M | $18.8M | 3.9% | 0.85 | $119M | $8.9M | $110.1M | $5M | $1.6M |
| FY2022 · to Dec 31 | $316.4M | — | −$35.3M | −$47.9M | -15.1% | -3.05 | −$31.2M | $8.9M | −$40.1M | $2M | $1.6M |
| FY2021 · to Dec 31 | $216.1M | — | −$39.8M | −$42.6M | -19.7% | -3.40 | $3.3M | $2.6M | $765K | $890K | $190K |
| FY2020 · to Dec 31 | $208.5M | 58.2% | −$16M | −$22.5M | -10.8% | -1.88 | $15.3M | $6.1M | $9.1M | $1.5M | $0 |
Every number comes from ANI PHARMACEUTICALS INC's own XBRL-tagged filings with the SEC, not a data vendor. Quarters marked derived are the fiscal year minus the three reported quarters, the same way every data provider computes Q4. Restated figures replace originals as later filings arrive.